Ocular Hypertension - Pipeline Insight, 2021
![](/report_cover/8047/ocular-hypertension-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Ocular Hypertension - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ocular Hypertension: Overview
Ocular hypertension is elevated intraocular pressure (IOP) without any evidence of glaucomatous optic neuropathy. It is not a disease; however, increased eye pressure is the most important risk factor in the development of open angle glaucoma. Ocular hypertension can be categorized similarly to glaucoma with various possible mechanisms of etiology associated with an open or closed (or narrow) angle and associated primary or secondary causes. Ocular hypertension has no noticeable signs or symptoms. If the pressure is too high there may be pain on eye movement or touch. Diagnosis is usually done by a doctor of optometry who will measure your eye pressure and compare it to normal.
'Ocular Hypertension - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Hypertension Emerging Drugs
Further product details are provided in the report……..
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.
Ocular Hypertension Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Ocular Hypertension - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ocular Hypertension: Overview
Ocular hypertension is elevated intraocular pressure (IOP) without any evidence of glaucomatous optic neuropathy. It is not a disease; however, increased eye pressure is the most important risk factor in the development of open angle glaucoma. Ocular hypertension can be categorized similarly to glaucoma with various possible mechanisms of etiology associated with an open or closed (or narrow) angle and associated primary or secondary causes. Ocular hypertension has no noticeable signs or symptoms. If the pressure is too high there may be pain on eye movement or touch. Diagnosis is usually done by a doctor of optometry who will measure your eye pressure and compare it to normal.
'Ocular Hypertension - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ocular Hypertension Emerging Drugs
- NCX 470: Nicox
- AGN 193408: AbbVie
- Sepetaprost DE-126: Santen Pharmaceutical
Further product details are provided in the report……..
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ocular Hypertension
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.
Ocular Hypertension Report Insights
- Ocular Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ocular Hypertension drugs?
- How many Ocular Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ocular Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
- Nicox
- Santen Pharmaceutical
- AbbVie
- MediPrint Ophthalmics
- Whitecap Biosciences
- Ocular Therapeutix
- Sylentis
- Chong Kun Dang Pharmaceutical
- Aerpio Pharmaceuticals
- NCX 470
- Sepetaprost DE-126
- AGN 193408
- LL-BMT1
- WB007
- Travoprost ophthalmic
- SYL040012
- CKD-351
- Razuprotafib
Introduction
Executive Summary
Ocular Hypertension: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ocular Hypertension – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ocular Hypertension companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ocular Hypertension Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
NCX 470: Nicox
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Sepetaprost DE-126: Santen Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ocular Hypertension Key Companies
Ocular Hypertension Key Products
Ocular Hypertension- Unmet Needs
Ocular Hypertension- Market Drivers and Barriers
Ocular Hypertension- Future Perspectives and Conclusion
Ocular Hypertension Analyst Views
Ocular Hypertension Key Companies
Appendix
Executive Summary
Ocular Hypertension: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ocular Hypertension – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ocular Hypertension companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ocular Hypertension Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
NCX 470: Nicox
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Sepetaprost DE-126: Santen Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ocular Hypertension Key Companies
Ocular Hypertension Key Products
Ocular Hypertension- Unmet Needs
Ocular Hypertension- Market Drivers and Barriers
Ocular Hypertension- Future Perspectives and Conclusion
Ocular Hypertension Analyst Views
Ocular Hypertension Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ocular Hypertension
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ocular Hypertension
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ocular Hypertension
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ocular Hypertension
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products